Creo Medical Group Plc

As of December 31, 2025, CREO MED GROUP LTD. carries a market capitalization of 82.75M, placing it among publicly traded companies globally. Its enterprise value stands at 71.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CREO MED GROUP LTD.'s next confirmed earnings release is scheduled for June 2, 2027.

As of December 31, 2025, CREO MED GROUP LTD. has 412.47M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, CREO MED GROUP LTD. maintains a current ratio of 3.22, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on September 25, 2026, CREO MED GROUP LTD.'s stock has declined approximately 18.92% over the past 52 weeks.

As of December 31, 2025, CREO MED GROUP LTD. holds 16.71M in cash and equivalents against 5.52M in total debt, resulting in a net debt position of -11.32M. Total book value stands at 67.37M, with working capital of 21.83M providing operational flexibility.

CREO MED GROUP LTD.'s most recent stock split took place on February 16, 2023.